Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer

BACKGROUND: Treatment options for pancreatic ductal adenocarcinoma (PDAC) are limited. Histone deacetylase inhibitors are a new and promising drug family with strong anticancer activity. The aim of this study was to examine the efficacy of in vitro and in vivo treatment with the novel pan-HDAC inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Dovzhanskiy, Dmitriy I, Arnold, Stefanie M, Hackert, Thilo, Oehme, Ina, Witt, Olaf, Felix, Klaus, Giese, Nathalia, Werner, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407493/
https://www.ncbi.nlm.nih.gov/pubmed/22681698
http://dx.doi.org/10.1186/1471-2407-12-226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407493/
https://www.ncbi.nlm.nih.gov/pubmed/22681698
http://dx.doi.org/10.1186/1471-2407-12-226

Ejemplares similares